Dosing schedule for a combination of ceritinib and an anti-PD-1 antibody molecule

• 收藏
• 分享

专利权人:

Novartis AG;Bristol-Myers Squibb

发明人:

Jeffrey, Scott

申请号：

AU2018223349

公开号：

AU2018223349A1

申请日:

2018.02.26

申请国别(地区):

AU

年份:

2019

代理人:

摘要：

The present disclosure relates to the field of pharmacy, particularly to ceritinib and a PD-1 inhibitor for use in the treatment of cancer. Specifically, the disclosure relates to a pharmaceutical combination comprising ceritinib, or a pharmaceutically acceptable salt thereof, and a PD-1 inhibitor, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, to a method for the treatment of cancer that involves administering the combination and to the use of the combination for the manufacture of a medicament for the treatment of cancer.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/